title: Dose escalation study with two different hypofractionated intensity modulated radiotherapy techniques for localized prostate cancer: acute toxicity.
abstract: To assess acute gastrointestinal (GI) and genitourinary (GU) toxicities in patients with localized prostate cancer treated with a sequential dose escalation hypofractionated intensity-modulated radiotherapy (IMRT) study using two different delivery methods. Since 2003, 88 and 48 patients were sequentially treated to 56 Gy and to 60 Gy (4 Gy/fraction twice weekly), respectively. IMRT with 6 MV beams was delivered with five fields in Geneva and with nine in Barcelona. Acute GI and GU side effects were scored weekly during treatment and 6 weeks after treatment completion using the Radiation Therapy Oncology Group (RTOG) toxicity scale. Clinical, technical, and dosimetric parameters were analyzed in order to assess for a potential correlation with toxicity. Grade 1-2, GU and GI toxicities during and 6 weeks after treatment completion were 64%, and 24%, and 35% and 12%, respectively. Only one Grade 4 GU toxicity, consisting of transitory urinary obstruction, was observed. Patients treated to 60 Gy in Geneva presented a higher rate of Grade 1-2 GU toxicity (p = 0.01), while patients treated to both 56 and 60 Gy in Barcelona presented a higher Grade 1-2 GI toxicity (p = 0.02). A lower rate of rectal toxicity was observed in the subgroup of 22 patients treated with a rectal balloon (p = 0.02). The use of androgen deprivation therapy was associated with a higher rate of Grade 1-2 GU toxicity after the end of the treatment (p = 0.02). Dose escalation with either 14 _ 4 Gy or 15 _ 4 Gy delivered with two different IMRT techniques is feasible and is associated with a tolerable acute toxicity.
authors.affiliation: Service de Radio-oncologie, Hopitaux Universitaires de Geneve, Geneva, Switzerland. thomaszilli@inwind.it
authors.forename: Thomas
authors.initials: T
authors.lastname: Zilli
authors.forename: Michel
authors.initials: M
authors.lastname: Rouzaud
authors.forename: Sandra
authors.initials: S
authors.lastname: Jorcano
authors.forename: Giovanna
authors.initials: G
authors.lastname: Dipasquale
authors.forename: Philippe
authors.initials: P
authors.lastname: Nouet
authors.forename: José Ignacio
authors.initials: JI
authors.lastname: Toscas
authors.forename: Nathalie
authors.initials: N
authors.lastname: Casanova
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.forename: Lluìs
authors.initials: L
authors.lastname: Escude
authors.forename: Meritxell
authors.initials: M
authors.lastname: Molla
authors.forename: Dolors
authors.initials: D
authors.lastname: Linero
authors.forename: Damien C
authors.initials: DC
authors.lastname: Weber
authors.forename: Raymond
authors.initials: R
authors.lastname: Miralbell
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods*
chemical_list: D017430:Prostate-Specific Antigen